Review



rat polyclonal cd19 antibody  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Novus Biologicals rat polyclonal cd19 antibody
    Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among <t>CD19+B</t> cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant
    Rat Polyclonal Cd19 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+polyclonal+cd19+antibody/pmc12930626-83-5-28?v=Novus+Biologicals
    Average 94 stars, based on 9 article reviews
    rat polyclonal cd19 antibody - by Bioz Stars, 2026-07
    94/100 stars

    Images

    1) Product Images from "IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis"

    Article Title: IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis

    Journal: Arthritis Research & Therapy

    doi: 10.1186/s13075-026-03735-8

    Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant
    Figure Legend Snippet: Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant

    Techniques Used: Expressing, Flow Cytometry, Staining, Clinical Proteomics, Immunofluorescence



    Similar Products

    rabbit polyclonal antibodies against rat cd19  (Bioss)
    92
    Bioss rabbit polyclonal antibodies against rat cd19
    Rabbit Polyclonal Antibodies Against Rat Cd19, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+polyclonal+cd19+antibody/pm26833819-47-30-39?v=Bioss
    Average 92 stars, based on 1 article reviews
    rabbit polyclonal antibodies against rat cd19 - by Bioz Stars, 2026-07
    92/100 stars
    		  Buy from Supplier
    rat polyclonal cd19 antibody  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology rat polyclonal cd19 antibody
    Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among <t>CD19+B</t> cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant
    Rat Polyclonal Cd19 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+polyclonal+cd19+antibody/pmc12930626-83-5-18?v=Santa+Cruz+Biotechnology
    Average 96 stars, based on 1 article reviews
    rat polyclonal cd19 antibody - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    rat polyclonal cd19 antibody  (Novus Biologicals)
    94
    Novus Biologicals rat polyclonal cd19 antibody
    Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among <t>CD19+B</t> cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant
    Rat Polyclonal Cd19 Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rat+polyclonal+cd19+antibody/pmc12930626-83-5-28?v=Novus+Biologicals
    Average 94 stars, based on 1 article reviews
    rat polyclonal cd19 antibody - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant

    Journal: Arthritis Research & Therapy

    Article Title: IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis

    doi: 10.1186/s13075-026-03735-8

    Figure Lengend Snippet: Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant

    Article Snippet: The following reagents were used: Rat polyclonal CD19 antibody (Columbia, MD, USA; Cat# 32727), a Mouse IL-6 antibody (Santa Cruz Biotechnology, USA; Cat# SC-28343), Mouse monoclonal CD19 antibody (Novus Biologicals, USA; Cat# NBP2-25196SS), Rat Anti-IL-10 antibody (Abcam, Cambridge, UK; Cat# ab133575), and Rat IL-35 Antibody (Abbexa, Cambridge, UK; Cat# Abx274658),

    Techniques: Expressing, Flow Cytometry, Staining, Clinical Proteomics, Immunofluorescence

    Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant

    Journal: Arthritis Research & Therapy

    Article Title: IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis

    doi: 10.1186/s13075-026-03735-8

    Figure Lengend Snippet: Expression levels of B cell subsets and related cytokines in peripheral blood of systemic sclerosis patients and healthy controls. A Flow cytometry gating strategy and staining patterns showing frequencies of B cells, interleukin-10+ regulatory B cells (IL-10+Breg), IL-35+Breg cells, and IL-6+ effector B cells (IL-6+Beff). B Plasma concentrations of IL-35, IL-10, B cell activating factor (BAFF), and IL-6. C Relative mRNA expression of IL-10, IL-6, and transforming growth factor-β1 (TGF-β1) in skin tissue. D Immunofluorescence images of IL-10+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). E Immunofluorescence images of IL-35+Breg cells in skin tissue and their proportion among CD19+B cells (scale bar: 50 μm, 400× magnification). F Heatmap showing correlations between circulating B cell subsets/cytokines and clinical parameters. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant

    Article Snippet: The following reagents were used: Rat polyclonal CD19 antibody (Columbia, MD, USA; Cat# 32727), a Mouse IL-6 antibody (Santa Cruz Biotechnology, USA; Cat# SC-28343), Mouse monoclonal CD19 antibody (Novus Biologicals, USA; Cat# NBP2-25196SS), Rat Anti-IL-10 antibody (Abcam, Cambridge, UK; Cat# ab133575), and Rat IL-35 Antibody (Abbexa, Cambridge, UK; Cat# Abx274658),

    Techniques: Expressing, Flow Cytometry, Staining, Clinical Proteomics, Immunofluorescence